Navigation

    Forum

    • Register
    • Login
    • Search
    • Categories
    • Recent
    • Popular
    • Users
    • Groups

    427 - Recently we've seen an APS that have been submitted where p-values were requested for safety data, otherwise it would not be admissible as data. The problem is, virtually no clinical trials power their adverse events to generate p-values. When did this become a requirement?

    Claims & Support/References for Claims
    1
    1
    60
    Loading More Posts
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes
    Reply
    • Reply as topic
    Log in to reply
    This topic has been deleted. Only users with topic management privileges can see it.
    • Jennifer Carroll
      Jennifer Carroll last edited by

      PAAB section 5.9 has required statistical analysis to support inclusion of comparative therapeutic data from clinical trials (whether active comparator or inactive comparator) for as long as I can remember. You might be thinking of comprehensive excerpts from the s/e tables of part 1 of the PM (which don’t require stats). PAAB can also consider claim neutral, non-comparative presentations of the incidences of sponsor drug’s side effects from an acceptable clinical trial provided those incidences are roughly aligned with the product monograph AND the product monograph’s most common adverse events (with incidences) are presented as copy specific balance copy.

      1 Reply Last reply Reply Quote 0
      • First post
        Last post